Pharmacogenetics of the nuclear hormone receptors: the missing link between environment and drug effects?

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Pharmacogenomics (London)

• Publication date

  2013-11-26

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2217/pgs.13.214PMID 24279858
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.

  2013cited by this paper
• Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment

  2013cited by this paper
• Genetic variants in the vitamin D pathway and breast cancer disease-free survival.

  2013cited by this paper
• Combined treatment with peroxisome proliferator-activated receptor (PPAR) gamma ligands and gamma radiation induces apoptosis by PPARγ-independent up-regulation of reactive oxygen species-induced deoxyribonucleic acid damage signals in non-small cell lung cancer cells.

  2013cited by this paper
• Pharmacogenetics of CYP1A2 activity and inducibility in smokers and exsmokers

  2013cited by this paper
• Correlates of Efavirenz Exposure in Chilean Patients Affected With Human Immunodeficiency Virus Reveals a Novel Association With a Polymorphism in the Constitutive Androstane Receptor

  2013cited by this paper
• Pregnane X receptor and human malignancy.

  2013cited by this paper
• Vitamin D receptor gene variants and clinical outcomes after androgen-deprivation therapy for prostate cancer

  2013cited by this paper
• Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.

  2013cited by this paper
• Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response.

  2013cited by this paper
• Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients

  2013cited by this paper
• A Novel Mechanism of PPAR Gamma Induction via EGFR Signalling Constitutes Rational for Combination Therapy in Bladder Cancer

  2013cited by this paper
• Nuclear receptors PXR and CAR: implications for drug metabolism regulation, pharmacogenomics and beyond

  2013cited by this paper
• Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib

  2013cited by this paper
• Marine sponge steroids as nuclear receptor ligands.

  2012cited by this paper
• The retinoid X receptors and their ligands.

  2012cited by this paper
• Pharmacogenetic Analysis of Pediatric Patients with Acute Lymphoblastic Leukemia: A Possible Association between Survival Rate and ITPA Polymorphism

  2012cited by this paper
• HNF4α: a new biomarker in colon cancer?

  2012cited by this paper
• In Silico and In Vitro Identification of MicroRNAs That Regulate Hepatic Nuclear Factor 4α Expression

  2012cited by this paper
• miRNA pharmacogenomics: the new frontier for personalized medicine in cancer?

  2012cited by this paper
• Regulatory role of KEAP1 and NRF2 in PPARγ expression and chemoresistance in human non-small-cell lung carcinoma cells.

  2012cited by this paper
• PPAR signaling pathway may be an important predictor of breast cancer response to neoadjuvant chemotherapy

  2012cited by this paper
• Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation.

  2012cited by this paper
• Very important pharmacogene summary for VDR

  2012cited by this paper
• Genetic polymorphisms of drug metabolizing enzymes and transporters: the long way from bench to bedside.

  2012cited by this paper
• Vitamin D receptor gene BsmI polymorphism B allele, but not BB genotype, is associated with systemic lupus erythematosus in a Han Chinese population

  2012cited by this paper
• Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters.

  2012cited by this paper
• Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response

  2012cited by this paper
• Peroxisome proliferator-activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells.

  2012cited by this paper
• Cisplatin-induced chemoresistance in colon cancer cells involves FXR-dependent and FXR-independent up-regulation of ABC proteins.

  2012cited by this paper
• Solomonamides A and B, new anti-inflammatory peptides from Theonella swinhoei.

  2011cited by this paper
• Evolution of promiscuous nuclear hormone receptors: LXR, FXR, VDR, PXR, and CAR.

  2011cited by this paper
• Pregnane X receptor (PXR/NR1I2) gene haplotypes modulate susceptibility to inflammatory bowel disease

  2011cited by this paper
• Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma.

  2011cited by this paper
• Global Assessment of Genetic Variation Influencing Response to Retinoid Chemoprevention in Head and Neck Cancer Patients

  2011cited by this paper
• Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.

  2011cited by this paper
• Vitamin D metabolism and action in the prostate: implications for health and disease.

  2011cited by this paper
• A Systematic Analysis of the 3′UTR of HNF4A mRNA Reveals an Interplay of Regulatory Elements Including miRNA Target Sites

  2011cited by this paper
• Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.

  2011cited by this paper
• The effect of vitamin D3 and ketoconazole combination on VDR-mediated P-gp expression and function in human colon adenocarcinoma cells: implications in drug disposition and resistance.

  2011cited by this paper
• Association of genetic markers in angiogenesis- or exposure-related genes with overall survival in pazopanib (P) treated patients (Pts) with advanced renal cell carcinoma.

  2011cited by this paper
• Cross-talk between androgen receptor and pregnane and xenobiotic receptor reveals existence of a novel modulatory action of anti-androgenic drugs.

  2010cited by this paper
• Pharmacogenetic risk factors for altered bone mineral density and body composition in pediatric acute lymphoblastic leukemia

  2010cited by this paper
• Genetic Variants in Inflammation-Related Genes Are Associated with Radiation-Induced Toxicity Following Treatment for Non-Small Cell Lung Cancer

  2010cited by this paper
• Vitamin D, disease and therapeutic opportunities

  2010cited by this paper
• A role for the pregnane X receptor in flucloxacillin‐induced liver injury

  2010cited by this paper
• Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.

  2010cited by this paper
• Orphan Nuclear Receptors as Targets for Drug Development

  2010cited by this paper
• A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform

  2010cited by this paper
• Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib

  2010cited by this paper
• Nuclear receptors as drug targets for metabolic disease.

  2010cited by this paper
• Pregnane × Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation

  2010cited by this paper
• PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line

  2009cited by this paper
• Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.

  2009cited by this paper
• CYP2D6 and tamoxifen: DNA matters in breast cancer

  2009cited by this paper
• Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide

  2009cited by this paper
• Association of Pregnane X Receptor with Multidrug Resistance-Related Protein 3 and its Role in Human Colon Cancer Chemoresistance

  2009cited by this paper
• Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.

  2009cited by this paper
• Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.

  2009cited by this paper
• Regulation of drug resistance by human pregnane X receptor in breast cancer

  2009cited by this paper
• The antiapoptotic role of pregnane X receptor in human colon cancer cells.

  2008cited by this paper
• Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel‐induced leukopenia

  2008cited by this paper
• Role of Pregnane X Receptor in Control of All-Trans Retinoic Acid (ATRA) Metabolism and Its Potential Contribution to ATRA Resistance

  2008cited by this paper
• Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.

  2008cited by this paper
• Post-transcriptional Regulation of Human Pregnane X Receptor by Micro-RNA Affects the Expression of Cytochrome P450 3A4*

  2008cited by this paper
• Expanding the Roles for Pregnane X Receptor in Cancer: Proliferation and Drug Resistance in Ovarian Cancer

  2008cited by this paper
• Human pregnane X receptor is expressed in breast carcinomas, potential heterodimers formation between hPXR and RXR-alpha

  2008cited by this paper
• PXR Pharmacogenetics: Association of Haplotypes with Hepatic CYP3A4 and ABCB1 Messenger RNA Expression and Doxorubicin Clearance in Asian Breast Cancer Patients

  2008cited by this paper
• PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics.

  2008cited by this paper
• Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.

  2008cited by this paper
• PXR, CAR and HNF4α genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients

  2008cited by this paper
• Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group.

  2008cited by this paper
• A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group.

  2008cited by this paper
• Synergism between vitamin D and secreted protein acidic and rich in cysteine–induced apoptosis and growth inhibition results in increased susceptibility of therapy-resistant colorectal cancer cells to chemotherapy

  2007cited by this paper
• The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology.

  2007cited by this paper
• Characterization of Vitamin D insensitive prostate cancer cells.

  2007cited by this paper
• Lack of Association of Single-Nucleotide Polymorphisms in Pregnane X Receptor, Hepatic Nuclear Factor 4α, and Constitutive Androstane Receptor with Docetaxel Pharmacokinetics

  2007cited by this paper
• Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer.

  2007cited by this paper
• Induction of multidrug resistance associated protein 2 in tamoxifen-resistant breast cancer cells.

  2007cited by this paper
• Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines

  2007cited by this paper
• Human pregnane X receptor and resistance to chemotherapy in prostate cancer.

  2007cited by this paper
• Down-Regulation of Pregnane X Receptor Contributes to Cell Growth Inhibition and Apoptosis by Anticancer Agents in Endometrial Cancer Cells

  2007cited by this paper
• The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression.

  2006cited by this paper
• SNAIL vs vitamin D receptor expression in colon cancer: therapeutics implications

  2005cited by this paper
• Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer

  2005cited by this paper
• Relationship of Systemic Exposure to Unbound Docetaxel and Neutropenia

  2005cited by this paper
• Induction of phase I, II and III drug metabolism/transport by xenobiotics

  2005cited by this paper
• The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells.

  2005cited by this paper
• Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma

  2004cited by this paper
• Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia.

  2004cited by this paper
• Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia.

  2004cited by this paper
• Genetics and biology of vitamin D receptor polymorphisms.

  2004cited by this paper
• Pharmacogenetics of outcome in children with acute lymphoblastic leukemia.

  2004cited by this paper
• Pharmacogenetics of the vitamin D receptor and osteoporosis.

  2001cited by this paper
• The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants.

  2001cited by this paper
• The worldwide controversy about the polymorphism of the vitamin D receptor gene and bone mineral density.

  2000cited by this paper
• The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB.

  2000cited by this paper
• Association of breast cancer progression with a vitamin D receptor gene polymorphism. South-East Sweden Breast Cancer Group.

  1999cited by this paper
• A Vitamin D Receptor Gene Polymorphism in the Translation Initiation Codon: Effect on Protein Activity and Relation to Bone Mineral Density in Japanese Women

  1997cited by this paper

• The Role of Nuclear Receptors in Metabolic Homeostasis and Disease: From Molecular Mechanisms to Drug Discovery.

  2025cites this paper
• Integration of germline pharmacogenomic burden to predict fluoropyrimidine-related toxicity – A secondary analysis of the PREPARE trial

  2025cites this paper
• Clinical Implementation of Rare and Novel DPYD Variants for Personalizing Fluoropyrimidine Treatment: Challenges and Opportunities

  2024cites this paper
• The burden of rare variants in DPYS gene is a novel predictor of the risk of developing severe fluoropyrimidine-related toxicity

  2023cites this paper
• Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm?

  2023cites this paper
• Predicting drug response and toxicity in metastatic colorectal cancer: the role of germline markers

  2022cites this paper
• Pharmacogenetics Role of Genetic Variants in Immune-Related Factors: A Systematic Review Focusing on mCRC

  2022cites this paper
• IL15RA and SMAD3 Genetic Variants Predict Overall Survival in Metastatic Colorectal Cancer Patients Treated with FOLFIRI Therapy: A New Paradigm

  2021cites this paper
• Genetic markers of the host to predict the efficacy of colorectal cancer targeted therapy.

  2019cites this paper
• Germline Polymorphisms in the Nuclear Receptors PXR and VDR as Novel Prognostic Markers in Metastatic Colorectal Cancer Patients Treated With FOLFIRI

  2019cites this paper
• A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy

  2018cites this paper
• Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation.

  2018cites this paper
• Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients

  2018cites this paper
• Vitamin D3 protects against prednisolone-induced liver injury associated with the impairment of the hepatic NF-κB/iNOS/NO pathway.

  2017cites this paper
• Bile Acids as Novel Pharmacological Agents: The Interplay Between Gene Polymorphisms, Epigenetic Factors and Drug Response.

  2016cites this paper
• Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine.

  2016cites this paper
• RXRα, PXR and CAR xenobiotic receptors mediate the apoptotic and neurotoxic actions of nonylphenol in mouse hippocampal cells.

  2016cites this paper
• Nuclear receptors and drug metabolism for the personalization of cancer therapy

  2016cites this paper
• PPARA gene and phenprocoumon: a new predictor of response variability.

  2015cites this paper
• Nuclear Receptor Signaling Atlas: Opening Access to the Biology of Nuclear Receptor Signaling Pathways

  2015cites this paper
• Apoptotic and neurotoxic actions of 4-para-nonylphenol are accompanied by activation of retinoid X receptor and impairment of classical estrogen receptor signaling.

  2014cites this paper
• Biology of PXR: role in drug-hormone interactions

  2014cites this paper